Review explores agentic AI systems optimizing pharmaceutical analytics with regulatory support, indicating transformative potential.
Agentic AI is investigated in relation to autonomous closed-loop pharmaceutical analytics within the scope of this review. It will cover frameworks for agentic AI-based pharmaceutical analytics as well as their systems architecture, incorporation into regulations, and practical application areas. Standardized and even AI-based methods used in pharmaceutical analysis still involve certain constraints related to static structure and human involvement. Agentic AI-based systems are goal-directed and self-adaptive, providing decision-making capabilities and optimization processes within closed-loop structures covering designing, executing, evaluating, and improving. Conceptual models of agentic AI-based systems include multi-agent system architecture, systems’ lifecycle validation model, and regulation-compliant AI. Potential benefits relate to reduced method development time up to 30–50%, increased robustness, and real-time performance control. Nevertheless, the following issues need to be solved: validation of an adaptive system, data integrity, lack of explainability, and difficulties with gaining regulatory approval. Prospects include the use of digital twins, federated learning, and explainable AI.
No takes yet. Share an insight, caveat, or question.
Gaikwad et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: